Skip to content

Xiamen Registry of Pregnant Women and Offspring (REPRESENT)

Xiamen Registry of Pregnant Women and Offspring (REPRESENT): A Population-based, Long-term Follow-up Database Linking Four Major Healthcare Data Platforms

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04222621
Enrollment
761194
Registered
2020-01-10
Start date
2008-01-31
Completion date
2023-12-31
Last updated
2020-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women, Registries

Keywords

Population-based healthcare database, Registry, Pregnant women and offspring, Longitudinal study

Brief summary

To improve the health of women and children under the background of Healthy China 2030, the investigators developed REPRESENT by establishing a pregnancy registry in Xiamen, a sub-provincial city of over four million residents in east China, based on the Maternal and Child Health Management Platform, and then linking to three other platforms, i.e. Residents Healthcare Management Platform, Primary Healthcare Management Platform, and Electronic Healthcare Records (EHR) Platform, which had been developed since 2006. The registry documented information and events about pregnant women from registration at their first trimester to postpartum, and includes the childhood follow up records. The registry not only enables longitudinal follow up of pregnant women and their offspring, but also expands the scope of database from pre-pregnancy exposures to long-term outcomes by data linkage. During the past 11 years (January 2008 to March 2019), the REPRESENT has accumulated data concerning more than 700 thousands pregnancies. The data volume is substantial with over 800 variables being documented, and most variables are designed as structured fields. The disease categories and codes are standardized according to the International Classification of Diseases 10th Revision (ICD-10). The whole process of data access, data extraction, data processing and data analysis was conducted through an internal-only accessible server at Xiamen Health and Medical Big Data Center. All investigators cannot access sensitive information, are required to sign data confidentiality agreement and should obtain approval by the Xiamen Health and Medical Big Data Center and the Chinese Evidence-based Medicine Center.

Interventions

OTHERPregnant women without intervention

Pregnant women with those exposures of interest determined in specific research based on the registry

Sponsors

Xiamen Health and Medical Big Data Center, Xiamen Health Commission
CollaboratorUNKNOWN
West China Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of ruptured uterusUp to 42 weeksRupture of maternal uterus confirmed by laparotomy.
Incidence of postpartum hemorrhageWithin 24h after deliveryPostpartum bleeding volume ≥500 mL.
Incidence of pre-eclampsiaUp to 42 weeksMaternal systolic blood pressure ≥ 140 mmHg and (or) diastolic pressure ≥ 90 mmHg, accompanied by any one of the following: urinary protein ≥ 0.3g/24 h, or the ratio of urinary protein and creatinine ≥ 0.3, or random urine protein ≥ (+) if quantitative urine protein is not available; no proteinuria but with any damages of heart, lung, liver, kidney and other important organs, or with abnormal changes of blood system, digestive system and nervous system, or placenta fetus involvement, etc.
Incidence of eclampsiaUp to 42 weeksTonic-clonic seizures (convulsions) in preeclampsia patients, including convulsions and coma, not due to pre-existing or organic brain disorders.
Incidence of gestational diabetesUp to 32 weeksBy oral glucose tolerance test between 24 and 28 gestational weeks (fasting glucose ≥5.1 mmol/L, 1-h glucose ≥10.0 mmol/L, 2-h glucose ≥8.5 mmol/L; one abnormal result sufficient).
Incidence of maternal deathUp to 52 weeksMaternal death
Incidence of birth defectsUp to 7 yearsBirth defects such as anencephaly, spina bifida, encephalocele, hydrocephalus, cleft palate, cleft lip, microtia, esophageal atresia or stenosis, anorectal, hypospadias, ectropion of bladder, talipes equinovarus, polydactylism, ankylodactylia, congenital diaphragmatic hernia, umbilical cord prolapse, gastroschisis, conjoined twins, down syndrome, congenital heart disease, or other birth defects.
Incidence of preterm birthUp to 37 weeksDelivery before 37th gestational weeks.
Incidence of neonatal birth weightUp to 42 weeksNeonatal birth weight measured after birth.
Incidence of neonatal deathWithin 28 days after deliveryNeonatal death
Incidence of stillbirthUp to 42 weeksFetus death at or after 20-28 weeks of gestation.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026